Symbols / VCNX
VCNX Chart
About
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate is pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 clinical for the treatment of Alzheimer's disease and has completed phase 2 study for the treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer; Pepinemab in combination with Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 clinical trial with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab and/or Ipilimumab which is in phase 2 clinical trial for melanoma; Pepinemab in combination with Trastuzumab and dendritic cell vaccines in phase 2 clinical trial for breast cancer. The company has also developed ActivMAb, a human antibody discovery platform based on a novel method for expressing and presenting complex multipass membrane proteins, as well as full-length human monoclonal antibodies on the surface of mammalian pox viruses. In addition, it develops CHS-114 and anti-CCR8 antibody; and VX5, which is in preclinical development to treat related to autoimmune disorders.It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; Emory University; Huntington Study Group; Catalent Pharma Solutions, LLC; and Surface Oncology, Inc. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.76M |
| Enterprise Value | 3.34M | Income | -18.63M | Sales | 601.00K |
| Book/sh | -1.55 | Cash/sh | 0.41 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | -7.36 | PEG | — |
| P/S | 4.59 | P/B | -0.66 | P/C | — |
| EV/EBITDA | -0.18 | EV/Sales | 5.56 | Quick Ratio | 0.38 |
| Current Ratio | 0.50 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -8.88 | EPS next Y | -0.14 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2021-08-16 08:00 | ROA | -3.76% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -15.90% | Profit Margin | 0.00% | Shs Outstand | 2.68M |
| Shs Float | 1.18M | Short Float | 3.23% | Short Ratio | 0.60 |
| Short Interest | — | 52W High | 1.50 | 52W Low | 0.25 |
| Beta | 0.69 | Avg Volume | 3.65K | Volume | 1.00 |
| Target Price | — | Recom | None | Prev Close | $1.03 |
| Price | $1.03 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
- New Alzheimer’s antibody trial gets $60M boost in search for treatment - Stock Titan ue, 23 Dec 2025 08
- Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - Stock Titan Fri, 07 Mar 2025 08
- Vaccinex, Inc. Faces Delisting from Nasdaq Due to Failure to Meet Continued Listing Standards - Nasdaq ue, 17 Dec 2024 08
- Vaccinex (VCNX) Stock Price, News & Analysis - MarketBeat Fri, 10 Aug 2018 22
- The 3 Best Biotech Stocks Under $1 to Buy for January - InvestorPlace hu, 26 Jan 2023 08
- Vaccinex (VCNX) Catches Eye: Stock Jumps 8.1% - Yahoo Finance ue, 07 Jul 2020 07
- VCNX - Vaccinex Inc Latest Stock News & Market Updates - Stock Titan Mon, 14 Sep 2020 09
- Is Vaccinex, Inc. (VCNX) Burning These Hedging Funds ? - Insider Monkey Mon, 25 Nov 2019 08
- Why Is Bed Bath & Beyond (BBBY) Stock Down 32% Today? - InvestorPlace ue, 07 Feb 2023 08
- Vaccinex's Pepinemab Breakthrough: New Data Shows Enhanced Cancer Immunotherapy Success - Stock Titan ue, 05 Nov 2024 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 30756 | 99957 | — | Stock Award(Grant) at price 3.25 per share. | FRIEDBERG ALBERT D | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-11-14 00:00:00 | I |
| 1 | 46153 | 149997 | — | Stock Award(Grant) at price 3.25 per share. | ZAUDERER MAURICE | Chief Executive Officer | — | 2024-11-14 00:00:00 | I |
| 2 | 240009 | 1352691 | — | Conversion of Exercise of derivative security at price 5.64 per share. | FRIEDBERG ALBERT D | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-09-18 00:00:00 | I |
| 3 | 113650 | 640531 | — | Conversion of Exercise of derivative security at price 5.64 per share. | ZAUDERER MAURICE | Chief Executive Officer | — | 2024-09-18 00:00:00 | I |
| 4 | 100 | 451 | — | Purchase at price 4.51 per share. | FRIEDBERG ALBERT D | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-08-09 00:00:00 | I |
| 5 | 6406 | 30349 | — | Purchase at price 4.60 - 4.92 per share. | FRIEDBERG ALBERT D | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-08-06 00:00:00 | I |
| 6 | 11703 | 55238 | — | Purchase at price 4.72 per share. | FRIEDBERG ALBERT D | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-08-01 00:00:00 | I |
| 7 | 200000 | 1084201 | — | Purchase at price 5.10 - 5.74 per share. | FRIEDBERG ALBERT D | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-07-31 00:00:00 | I |
| 8 | 1818 | 9210 | — | Purchase at price 4.95 - 5.20 per share. | FRIEDBERG ALBERT D | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-05-30 00:00:00 | I |
| 9 | 543 | 3122 | — | Stock Award(Grant) at price 5.75 per share. | VAN STRYDONCK GERALD E | Director | — | 2024-05-10 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -18.60M | -21.85M | -19.61M | -22.28M |
| TotalUnusualItems | 62.00K | 1.72M | 0.00 | 876.00K |
| TotalUnusualItemsExcludingGoodwill | 62.00K | 1.72M | 0.00 | 876.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -18.63M | -20.25M | -19.82M | -22.38M |
| ReconciledDepreciation | 94.00K | 119.00K | 207.00K | 169.00K |
| ReconciledCostOfRevenue | 0.00 | |||
| EBITDA | -18.54M | -20.13M | -19.61M | -21.40M |
| EBIT | -18.63M | -20.25M | -19.81M | -21.57M |
| NetInterestIncome | -2.00K | -1.00K | -2.00K | -809.00K |
| InterestExpense | 2.00K | 1.00K | 2.00K | 809.00K |
| NormalizedIncome | -18.70M | -21.97M | -19.82M | -23.26M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -18.63M | -20.25M | -19.82M | -22.38M |
| TotalExpenses | 19.34M | 23.45M | 20.18M | 23.39M |
| TotalOperatingIncomeAsReported | -18.73M | -22.89M | -19.91M | -22.49M |
| DilutedAverageShares | 463.65K | 202.08K | 137.38K | |
| BasicAverageShares | 463.65K | 202.08K | 137.38K | |
| DilutedEPS | -43.68 | -98.05 | -163.80 | |
| BasicEPS | -43.68 | -98.05 | -163.80 | |
| DilutedNIAvailtoComStockholders | -18.63M | -20.25M | -19.82M | -22.38M |
| NetIncomeCommonStockholders | -18.63M | -20.25M | -19.82M | -22.38M |
| NetIncome | -18.63M | -20.25M | -19.82M | -22.38M |
| MinorityInterests | 0.00 | |||
| NetIncomeIncludingNoncontrollingInterests | -18.63M | -20.25M | -19.82M | -22.38M |
| NetIncomeContinuousOperations | -18.63M | -20.25M | -19.82M | -22.38M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -18.63M | -20.25M | -19.82M | -22.38M |
| OtherIncomeExpense | 103.00K | 2.63M | 93.00K | 919.00K |
| OtherNonOperatingIncomeExpenses | 41.00K | 912.00K | 93.00K | 43.00K |
| SpecialIncomeCharges | 0.00 | 876.00K | ||
| OtherSpecialCharges | -876.00K | |||
| GainOnSaleOfSecurity | 62.00K | 1.72M | ||
| NetNonOperatingInterestIncomeExpense | -2.00K | -1.00K | -2.00K | -809.00K |
| InterestExpenseNonOperating | 2.00K | 1.00K | 2.00K | 809.00K |
| OperatingIncome | -18.73M | -22.89M | -19.91M | -22.49M |
| OperatingExpense | 19.34M | 23.45M | 20.18M | 23.39M |
| OtherOperatingExpenses | -175.00K | |||
| ResearchAndDevelopment | 12.54M | 16.57M | 13.98M | 17.16M |
| SellingGeneralAndAdministration | 6.79M | 6.88M | 6.20M | 6.23M |
| GeneralAndAdministrativeExpense | 6.79M | 6.88M | 6.20M | 6.23M |
| OtherGandA | 6.79M | 6.88M | 6.20M | 6.23M |
| GrossProfit | 900.00K | |||
| CostOfRevenue | 0.00 | |||
| TotalRevenue | 601.00K | 570.00K | 275.00K | 900.00K |
| OperatingRevenue | 601.00K | 570.00K | 275.00K | 900.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 5.00 | 4.00 | 4.00 | 4.00 |
| OrdinarySharesNumber | 2.68M | 892.62K | 237.53K | 146.67K |
| ShareIssued | 2.68M | 892.62K | 237.53K | 146.68K |
| TotalDebt | 25.00K | 247.00K | 485.00K | 390.00K |
| TangibleBookValue | -4.15M | -2.31M | 5.19M | 7.41M |
| InvestedCapital | -4.13M | -2.21M | 5.37M | 7.66M |
| WorkingCapital | -2.55M | -2.57M | 4.94M | 7.15M |
| NetTangibleAssets | -2.49M | -2.31M | 5.19M | 7.41M |
| CapitalLeaseObligations | 0.00 | 146.00K | 310.00K | 141.00K |
| CommonStockEquity | -4.15M | -2.31M | 5.19M | 7.41M |
| PreferredStockEquity | 1.67M | |||
| TotalCapitalization | -2.49M | -2.29M | 5.29M | 7.59M |
| TotalEquityGrossMinorityInterest | -2.49M | -2.31M | 5.19M | 7.41M |
| MinorityInterest | 0.00 | |||
| StockholdersEquity | -2.49M | -2.31M | 5.19M | 7.41M |
| TreasuryStock | 11.00K | 11.00K | 11.00K | 11.00K |
| RetainedEarnings | -358.56M | -339.93M | -319.68M | -299.86M |
| AdditionalPaidInCapital | 354.42M | 337.63M | 324.88M | 307.28M |
| CapitalStock | 1.67M | 0.00 | 0.00 | 3.00K |
| CommonStock | 1.00K | 0.00 | 0.00 | 3.00K |
| PreferredStock | 1.67M | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 5.08M | 5.94M | 2.78M | 2.43M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 26.00K | 247.00K | 175.00K |
| LongTermDebtAndCapitalLeaseObligation | 26.00K | 247.00K | 175.00K | |
| LongTermCapitalLeaseObligation | 0.00 | 146.00K | 0.00 | |
| LongTermDebt | 26.00K | 101.00K | 175.00K | |
| CurrentLiabilities | 5.08M | 5.92M | 2.54M | 2.26M |
| OtherCurrentLiabilities | 2.35M | |||
| CurrentDeferredLiabilities | 0.00 | 63.00K | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 63.00K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 25.00K | 221.00K | 238.00K | 215.00K |
| CurrentCapitalLeaseObligation | 0.00 | 146.00K | 164.00K | 141.00K |
| CurrentDebt | 25.00K | 75.00K | 74.00K | 74.00K |
| OtherCurrentBorrowings | 25.00K | 75.00K | 74.00K | 74.00K |
| PayablesAndAccruedExpenses | 5.06M | 3.28M | 2.30M | 2.04M |
| CurrentAccruedExpenses | 1.10M | 1.24M | 781.00K | 980.00K |
| InterestPayable | 0.00 | |||
| Payables | 3.96M | 2.04M | 1.52M | 1.06M |
| AccountsPayable | 3.96M | 2.04M | 1.52M | 1.06M |
| TotalAssets | 2.60M | 3.63M | 7.98M | 9.84M |
| TotalNonCurrentAssets | 65.00K | 283.00K | 499.00K | 438.00K |
| NetPPE | 65.00K | 283.00K | 499.00K | 438.00K |
| AccumulatedDepreciation | -7.18M | -7.09M | -7.26M | -7.05M |
| GrossPPE | 7.25M | 7.37M | 7.75M | 7.49M |
| Leases | 3.28M | 3.28M | 3.26M | 3.21M |
| OtherProperties | 3.37M | 3.50M | 3.83M | 3.64M |
| MachineryFurnitureEquipment | 600.00K | 600.00K | 671.00K | 634.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.53M | 3.35M | 7.48M | 9.40M |
| OtherCurrentAssets | 586.00K | 853.00K | 912.00K | 816.00K |
| HedgingAssetsCurrent | 0.00 | 0.00 | ||
| PrepaidAssets | 816.00K | |||
| Receivables | 838.00K | 961.00K | 175.00K | 0.00 |
| AccountsReceivable | 838.00K | 961.00K | 175.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 1.11M | 1.53M | 6.39M | 8.59M |
| CashAndCashEquivalents | 1.11M | 1.53M | 6.39M | 8.59M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.21M | -21.45M | -19.17M | -25.33M |
| RepaymentOfDebt | -76.00K | -74.00K | -75.00K | -8.54M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 8.82M | 12.27M | 17.05M | 32.85M |
| CapitalExpenditure | -22.00K | -67.00K | -99.00K | -32.00K |
| EndCashPosition | 1.11M | 1.53M | 6.39M | 8.59M |
| BeginningCashPosition | 1.53M | 6.39M | 8.59M | 10.60M |
| ChangesInCash | -428.00K | -4.86M | -2.20M | -2.01M |
| FinancingCashFlow | 15.78M | 16.59M | 16.98M | 23.32M |
| CashFlowFromContinuingFinancingActivities | 15.78M | 16.59M | 16.98M | 23.32M |
| NetOtherFinancingCharges | -985.00K | |||
| ProceedsFromStockOptionExercised | 7.03M | 4.39M | 0.00 | |
| NetPreferredStockIssuance | 1.70M | 0.00 | ||
| PreferredStockIssuance | 1.70M | 0.00 | ||
| NetCommonStockIssuance | 7.12M | 12.27M | 17.05M | 32.85M |
| CommonStockIssuance | 7.12M | 12.27M | 17.05M | 32.85M |
| NetIssuancePaymentsOfDebt | -76.00K | -74.00K | -75.00K | -8.54M |
| NetLongTermDebtIssuance | -76.00K | -74.00K | -75.00K | -8.54M |
| LongTermDebtPayments | -76.00K | -74.00K | -75.00K | -8.54M |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -22.00K | -67.00K | -99.00K | -32.00K |
| CashFlowFromContinuingInvestingActivities | -22.00K | -67.00K | -99.00K | -32.00K |
| NetPPEPurchaseAndSale | -22.00K | -67.00K | -99.00K | -32.00K |
| PurchaseOfPPE | -22.00K | -67.00K | -99.00K | -32.00K |
| OperatingCashFlow | -16.19M | -21.38M | -19.07M | -25.30M |
| CashFlowFromContinuingOperatingActivities | -16.19M | -21.38M | -19.07M | -25.30M |
| ChangeInWorkingCapital | 2.10M | 318.00K | -11.00K | -3.21M |
| ChangeInOtherWorkingCapital | -63.00K | 63.00K | ||
| ChangeInPayablesAndAccruedExpense | 1.78M | 982.00K | 258.00K | -3.06M |
| ChangeInAccruedExpense | -138.00K | 461.00K | -199.00K | -957.00K |
| ChangeInPayable | 1.91M | 521.00K | 457.00K | -2.11M |
| ChangeInAccountPayable | 1.91M | 521.00K | 457.00K | -2.11M |
| ChangeInPrepaidAssets | 267.00K | 59.00K | -94.00K | -302.00K |
| ChangeInReceivables | 123.00K | -786.00K | -175.00K | 157.00K |
| ChangesInAccountReceivables | 123.00K | -786.00K | -175.00K | 157.00K |
| OtherNonCashItems | -1.29M | -2.11M | 458.00K | |
| StockBasedCompensation | 341.00K | 474.00K | 545.00K | 541.00K |
| DepreciationAmortizationDepletion | 94.00K | 119.00K | 207.00K | 169.00K |
| DepreciationAndAmortization | 94.00K | 119.00K | 207.00K | 169.00K |
| Depreciation | 94.00K | 119.00K | 207.00K | 169.00K |
| OperatingGainsLosses | 1.20M | 67.00K | -876.00K | |
| GainLossOnInvestmentSecurities | 1.20M | 67.00K | ||
| NetIncomeFromContinuingOperations | -18.63M | -20.25M | -19.82M | -22.38M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VCNX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|